Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 53: 1007-1009, 2007; 10.1373/clinchem.2007.087056
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klein, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klein, R. D.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2007;53:1007-1009.)
© 2007 American Association for Clinical Chemistry, Inc.


Editorials

The Pain Protective Haplotype: Introducing the Modern Genetic Test

Roger D. Klein

Yale University School of Medicine, Department of Genetics, 333 Cedar St., New Haven, CT 06510, Fax 216-896-0568, E-mail roger.klein@yale.edu

The first 300 words of the full text of this article appear below.

Chronic pain is a major health problem, affecting 2%–46.5% of adult populations (1)(2). In the United States, common pain conditions account for approximately $61.2 billion in lost workplace time (3). The human sensation of pain is affected by an individual’s past experiences, health status, psychological state, cultural and ethnic backgrounds, pain-coping skills, age, sex, and even pending litigation (4)(5). Emotional variables profoundly influence the perception of painful stimuli (6). In addition, genetic contributions to the experience of pain have increasingly been recognized (7). However, the complexity of pain processing, the multiplicity of influences on it, and the sensation’s inherent subjectivity and protean manifestations make the elucidation of relevant heritable factors extremely challenging.

Neuropathic pain is caused by injury to, or dysfunction of, the peripheral or central nervous system (8). It is particularly troublesome because of its prevalence, severity, chronicity, and resistance to therapy (9). Patients with conditions as diverse as diabetes mellitus, alcoholism, HIV, multiple sclerosis, postherpetic neuralgia, and spinal radiculopathies may suffer from chronic neuropathic pain. Radiculopathic pain is among the most frequently encountered neuropathic pain syndromes (8)(9).

Sciatica associated with intervertebral disc herniation is the most common type of radicular leg pain in adult working populations (10). Although many patients with herniated discs have favorable outcomes with medical therapy, individuals who have ongoing or severe pain often undergo lumbar discectomy. Recently, Tegeder et al. (11) described a putative association between an apparently common haplotype (15.4% of alleles in the study population) of the GTP cyclohydrolase gene (dopa-responsive dystonia, GCH1) and lower degrees of persistent pain after back surgery.

GTP cyclohydrolase is the rate-limiting enzyme in tetrahydrobiopterin (BH4) synthesis. BH4 serves as . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
J Law Med EthicsHome page
R. D. Klein and M. J. Mahoney
LabCorp v. Metabolite Laboratories: The Supreme Court Listens, but Declines to Speak.
J. Law Med. Ethics, March 1, 2008; 36(1): 141 - 149.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.